Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IBRX
IBRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IBRX News
Anktiva Receives Conditional Approval Recommendation in EU
1d ago
stocktwits
Market Dynamics of Heavily Shorted Stocks
1d ago
Benzinga
Pomerantz LLP Investigates ImmunityBio for Securities Fraud
2d ago
PRnewswire
Immunitybio Launches Mid-Stage Clinical Study for iNHL
Feb 02 2026
stocktwits
Market Analysis of Heavily Shorted Stocks
Feb 02 2026
Benzinga
ImmunityBio Launches Phase 2 Study of CAR-NK Cell Therapy for iNHL
Feb 02 2026
Yahoo Finance
Three Companies Achieve Best Monthly Performance
Jan 30 2026
Benzinga
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
Jan 28 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
Jan 28 2026
Newsfilter
Pomerantz LLP Investigates Securities Fraud Claims Against ImmunityBio
Jan 27 2026
Globenewswire
ImmunityBio Shares Surge 17% on FDA Update
Jan 26 2026
Fool
ImmunityBio Updates on Brain Tumor Trial Progress
Jan 26 2026
stocktwits
Market Risk Aversion Grows as Gold Prices Hit Record Highs
Jan 26 2026
stocktwits
ImmunityBio (IBRX) Shares Drop 12.13% Despite 207.14% Monthly Surge
Jan 23 2026
Fool
ImmunityBio (IBRX) Phase 2 Trial Update: 23 Patients Enrolled, Median Survival Not Yet Achieved
Jan 23 2026
stocktwits
ImmunityBio's QUILT-3.078 Study Shows 19 Patients Alive, Median Survival Not Yet Reached
Jan 23 2026
Newsfilter
Show More News
